

References

- Abdelgalil, A. A., & Alkahtani, H. M. (2022). Lapatinib: A comprehensive profile. *Profiles of Drug Substances, Excipients, and Related Methodology*, 135–166. <https://doi.org/10.1016/bs.podrm.2022.11.005>
- Adediji, A., Sroithongmoon, A., Suroengrit, A., Wilasluck, P., Deetanya, P., Sanachai, K., Karnchanapandh, K., Boonyasuppayakorn, S., Wangkanont, K., Rungrotmongkol, T., & Khotavivattana, T. (2025). Design, Synthesis, and Antiviral Activity of Fragmented-Lapatinib Aminoquinazoline Analogs towards SARS-CoV-2 Inhibition. *European Journal of Medicinal Chemistry*, 117303. <https://doi.org/10.1016/j.ejmech.2025.117303>
- Amaral, J. K., Bilsborrow, J. B., & Schoen, R. T. (2019). Chronic chikungunya arthritis and rheumatoid arthritis: What they have in common. *The American Journal of Medicine*, 133(3), e91–e97. <https://doi.org/10.1016/j.amjmed.2019.10.005>
- Bae, S., Lee, J. Y., & Myoung, J. (2019). Chikungunya Virus-Encoded NSP2, E2 and E1 strongly antagonize the interferon- γ Signaling pathway. *Journal of Microbiology and Biotechnology*, 29(11), 1852–1859. <https://doi.org/10.4014/jmb.1910.10014>
- Baer, A., & Kehn-Hall, K. (2014). Viral concentration determination through plaque assays: using traditional and novel overlay systems. *Journal of Visualized Experiments*, 93. <https://doi.org/10.3791/52065>
- Battisti, V., Urban, E., & Langer, T. (2021). Antivirals against the Chikungunya Virus. *Viruses*, 13(7), 1307. <https://doi.org/10.3390/v13071307>
- Biteghe, F. a. N., Toung, C. N. E., De La Croix Ndong, J., Mungra, N., Dar, T. B., & Kombe, A. J. K. (2021). Treatment of chikungunya virus (CHIKV) using targeted immunotherapy. In *Infectious diseases*. <https://doi.org/10.5772/intechopen.97811>
- Carlin, C. R. (2022). Role of EGF receptor regulatory networks in the host response to viral infections. *Frontiers in Cellular and Infection Microbiology*, 11. <https://doi.org/10.3389/fcimb.2021.820355>

Centers for Disease Control and Prevention (CDC). (2024). *Chikungunya / CDC Yellow Book 2024*.

Centers for Disease Control and Prevention.

<https://wwwnc.cdc.gov/travel/yellowbook/2024/infections-diseases/chikungunya#epi>

Chen, H., Lao, Z., Xu, J., Li, Z., Long, H., Li, D., Lin, L., Liu, X., Yu, L., Liu, W., Li, G., & Wu, J. (2020).

Antiviral activity of lycorine against Zika virus in vivo and in vitro. *Virology*, 546, 88–97.

<https://doi.org/10.1016/j.virol.2020.04.009>

Constant, L. E. C., Rajsfus, B. F., Carneiro, P. H., Sisnande, T., Mohana-Borges, R., & Allonso, D. (2021).

Overview on Chikungunya virus infection: From epidemiology to State-of-the-Art Experimental models. *Frontiers in Microbiology*, 12.

<https://doi.org/10.3389/fmicb.2021.744164>

Couderc, T., & Lecuit, M. (2015). Chikungunya virus pathogenesis: From bedside to bench. *Antiviral*

Research, 121, 120–131. <https://doi.org/10.1016/j.antiviral.2015.07.002>

De La Camara, C. M., McClements, M., & MacLaren, R. (2021). Accurate quantification of AAV vector

genomes by quantitative PCR. *Genes*, 12(4), 601. <https://doi.org/10.3390/genes12040601>

Elkamhawy, A., Son, S., Lee, H. Y., El-Maghrabey, M. H., Hamd, M. a. E., Alshammari, S. O.,

Abdelhameed, A. A., Alshammari, Q. A., Abdeen, A., Ibrahim, S. F., Mahdi, W. A., Alshehri, S.,

Alnajjar, R., Choi, W. J., Al-Karmalawy, A. A., & Lee, K. (2022). Design, synthesis, biological evaluation, and molecular dynamics studies of novel lapatinib derivatives. *Pharmaceuticals*,

16(1), 43. <https://doi.org/10.3390/ph16010043>

European Centre for Disease Prevention and Control. (2024, October 7). *Chikungunya worldwide overview*.

[https://www.ecdc.europa.eu/en/chikungunya-monthly#:~:text=Map-,Chikungunya%20virus%20disease%20case%20notification%20rate%20per,population%2C%20August%202023%2DJuly%202024&text=2%20Sep%202024-,In%202024%20and%20as%20of%2031%20of%20July%2C%20approximately%20450,\)%20and%20Africa%20\(1\).](https://www.ecdc.europa.eu/en/chikungunya-monthly#:~:text=Map-,Chikungunya%20virus%20disease%20case%20notification%20rate%20per,population%2C%20August%202023%2DJuly%202024&text=2%20Sep%202024-,In%202024%20and%20as%20of%2031%20of%20July%2C%20approximately%20450,)%20and%20Africa%20(1).)

- European Centre for Disease Prevention and Control (ECDC). (2024, October 7). *Chikungunya worldwide overview*. European Centre for Disease Prevention and Control. [https://www.ecdc.europa.eu/en/chikungunya-monthly#:~:text=Map-,Chikungunya%20virus%20disease%20case%20notification%20rate%20per,population%2C%20August%202023%2DJuly%202024&text=2%20Sep%202024-,In%202024%20and%20as%20of%2031%20of%20July%2C%20approximately%20450,\)%20and%20Africa%20\(1\).](https://www.ecdc.europa.eu/en/chikungunya-monthly#:~:text=Map-,Chikungunya%20virus%20disease%20case%20notification%20rate%20per,population%2C%20August%202023%2DJuly%202024&text=2%20Sep%202024-,In%202024%20and%20as%20of%2031%20of%20July%2C%20approximately%20450,)%20and%20Africa%20(1).)
- Freppel, W., Silva, L. A., Stapleford, K. A., & Herrero, L. J. (2024). Pathogenicity and virulence of chikungunya virus. *Virulence*, 15(1). <https://doi.org/10.1080/21505594.2024.2396484>
- Galán-Huerta, K., Rivas-Estilla, A., Fernández-Salas, I., Farfan-Ale, J., & Ramos-Jiménez, J. (2015). Chikungunya virus: A general overview. *Medicina Universitaria*, 17(68), 175–183. <https://doi.org/10.1016/j.rmu.2015.06.001>
- Ganesan, V., Duan, B., & Reid, S. (2017). Chikungunya virus: Pathophysiology, mechanism, and modeling. *Viruses*, 9(12), 368. <https://doi.org/10.3390/v9120368>
- Gasque, P., Bandjee, M. C. J., Reyes, M. M., & Viasus, D. (2016). Chikungunya pathogenesis: From the clinics to the bench. *The Journal of Infectious Diseases*, 214(suppl 5), S446–S448. <https://doi.org/10.1093/infdis/jiw362>
- Gil, D., Zarzycka, M., Pabijan, J., Lekka, M., & Dulińska-Litewka, J. (2023). Dual targeting of melanoma translation by MNK/eIF4E and PI3K/mTOR inhibitors. *Cellular Signalling*, 109, 110742. <https://doi.org/10.1016/j.cellsig.2023.110742>
- Hakim, M. S., & Aman, A. T. (2022). Understanding the biology and immune pathogenesis of chikungunya virus infection for diagnostic and vaccine development. *Viruses*, 15(1), 48. <https://doi.org/10.3390/v15010048>
- Hangyu, W., Panpan, L., Jie, S., Hongyan, W., Linmiao, W., Kangning, H., Yichen, S., Shuai, W., & Cheng, W. (2024). Advancements in Antiviral Drug Development: Comprehensive Insights into Design Strategies and Mechanisms Targeting Key Viral Proteins. *Journal of Microbiology and Biotechnology*, 34(7), 1376–1384. <https://doi.org/10.4014/jmb.2403.03008>

- Hasler, F., Duda, A., Kündig, T. M., & Johansen, P. (2021). A tissue culture infectious dose-derived protocol for testing of SARS-CoV-2 neutralization of serum antibodies on adherent cells. *STAR Protocols*, 2(4), 100824. <https://doi.org/10.1016/j.xpro.2021.100824>
- Hucke, F. I. L., & Bugert, J. J. (2020). Current and promising antivirals against chikungunya virus. *Frontiers in Public Health*, 8. <https://doi.org/10.3389/fpubh.2020.618624>
- Hwu, J. R., Kapoor, M., Gupta, N. K., Tsay, S., Huang, W., Tan, K., Hu, Y., Lyssen, P., & Neyts, J. (2022). Synthesis and antiviral activities of quinazolinamine–coumarin conjugates toward chikungunya and hepatitis C viruses. *European Journal of Medicinal Chemistry*, 232, 114164. <https://doi.org/10.1016/j.ejmech.2022.114164>
- Hwu, J. R., Roy, A., Tsay, S., Huang, W., Lin, C., Hwang, K. C., Hu, Y., Shieh, F., Leyssen, P., & Neyts, J. (2022). Computer-Aided Design and Synthesis of (Functionalized quinazoline)–(α -substituted coumarin)–arylsulfonate Conjugates against Chikungunya Virus. *International Journal of Molecular Sciences*, 23(14), 7646. <https://doi.org/10.3390/ijms23147646>
- Long, K. M., & Heise, M. T. (2015). Protective and pathogenic responses to chikungunya virus infection. *Current Tropical Medicine Reports*, 2(1), 13–21. <https://doi.org/10.1007/s40475-015-0037-z>
- Metz, S. W., & Pijlman, G. P. (2016). Function of chikungunya virus structural proteins. In *Springer eBooks* (pp. 63–74). https://doi.org/10.1007/978-3-319-42958-8_5
- National Center for Biotechnology Information. (2025a). *PubChem Compound Summary for CID 208908, Lapatinib*. PubChem. Retrieved June 4, 2025, from <https://pubchem.ncbi.nlm.nih.gov/compound/Lapatinib>
- National Center for Biotechnology Information. (2025b). *PubChem Compound Summary for CID 324081, 4-Anilinoquinazoline*. PubChem. Retrieved June 4, 2025, from <https://pubchem.ncbi.nlm.nih.gov/compound/4-Anilinoquinazoline>

- Ng, W. H., Amaral, K., Javelle, E., & Mahalingam, S. (2024). Chronic chikungunya disease (CCD): clinical insights, immunopathogenesis and therapeutic perspectives. *QJM*.
<https://doi.org/10.1093/qjmed/hcae028>
- Niranjan, A., & Gupta, P. (2019, April 30). *Recent Trends in Chikungunya Virus diagnosis*.
<https://www.ijtimes.com/index.php/ijtimes/article/view/3068>
- Pattnaik, G. P., & Chakraborty, H. (2020). Entry inhibitors: Efficient means to block viral infection. *The Journal of Membrane Biology*, 253(5), 425–444. <https://doi.org/10.1007/s00232-020-00136-z>
- Puranik, N. V., Rani, R., Singh, V. A., Tomar, S., Puntambekar, H. M., & Srivastava, P. (2019). Evaluation of the Antiviral Potential of Halogenated Dihydrorugosaflavonoids and Molecular Modeling with nsP3 Protein of Chikungunya Virus (CHIKV). *ACS Omega*, 4(23), 20335–20345.
<https://doi.org/10.1021/acsomega.9b02900>
- Raymonda, M., Ciesla, J., Monaghan, M., Leach, J., Asantewaa, G., Smorodintsev-Schiller, L., Lutz, M., Schafer, X., Takimoto, T., Dewhurst, S., Munger, J., & Harris, I. (2021). Pharmacologic profiling reveals lapatinib as a novel antiviral against SARS-CoV-2 in vitro. *Virology*, 566, 60–68.
<https://doi.org/10.1016/j.virol.2021.11.008>
- Reis, E. V. S., Damas, B. M., Mendonça, D. C., Abrahão, J. S., & Bonjardim, C. A. (2021). In-Depth characterization of the Chikungunya virus replication cycle. *Journal of Virology*, 96(3).
<https://doi.org/10.1128/jvi.01732-21>
- Rodriguez, J. a. O., Haftel, A., & Walker, J. R., III. (2023, June 26). *Chikungunya fever*. StatPearls - NCBI Bookshelf. <https://www.ncbi.nlm.nih.gov/books/NBK534224/>
- Rozman, B., Fisher, T., & Stern-Ginossar, N. (2022). Translation—A tug of war during viral infection. *Molecular Cell*, 83(3), 481–495. <https://doi.org/10.1016/j.molcel.2022.10.012>
- Saha, A., Acharya, B. N., Parida, M., Saxena, N., Rajaiya, J., & Dash, P. K. (2023). Identification of 2,4-Diaminoquinazoline Derivative as a Potential Small-Molecule Inhibitor against Chikungunya and Ross River Viruses. *Viruses*, 15(11), 2194.
<https://doi.org/10.3390/v15112194>

- Shahrtash, S. A., Ghnim, Z. S., Ghaheiri, M., Adabi, J., Hassanzadeh, M. A., Yasamineh, S., Afkhami, H., Kheirkhah, A. H., Gholizadeh, O., & Moghadam, H. Z. (2024). Recent advances in the role of different nanoparticles in the various biosensors for the detection of the chikungunya virus. *Molecular Biotechnology*. <https://doi.org/10.1007/s12033-024-01052-6>
- Sharma, K. B., Subramani, C., Ganesh, K., Sharma, A., Basu, B., Balyan, S., Sharma, G., Ka, S., Deb, A., Srivastava, M., Chugh, S., Sehrawat, S., Bharadwaj, K., Rout, A., Sahoo, P. K., Saurav, S., Motiani, R. K., Singh, R., Jain, D., . . . Vratil, S. (2024). Withaferin A inhibits Chikungunya virus nsP2 protease and shows antiviral activity in the cell culture and mouse model of virus infection. *PLoS Pathogens*, 20(12), e1012816. <https://doi.org/10.1371/journal.ppat.1012816>
- Silva, L. A., & Dermody, T. S. (2017). Chikungunya virus: epidemiology, replication, disease mechanisms, and prospective intervention strategies. *Journal of Clinical Investigation*, 127(3), 737–749. <https://doi.org/10.1172/jci84417>
- Sornprasert, S., Jaratsittisin, J., Chumchanchira, C., & Smith, D. R. (2025). Effects of the fatty acid synthase inhibitors triclosan and lapatinib on dengue virus and Zika virus infection. *Scientific Reports*, 15(1). <https://doi.org/10.1038/s41598-025-95346-7>
- Uttam, S., Wong, C., Price, T. J., & Khoutorsky, A. (2018). EIF4E-Dependent Translational Control: a central Mechanism for Regulation of pain plasticity. *Frontiers in Genetics*, 9. <https://doi.org/10.3389/fgene.2018.00470>
- Von Delft, A., Hall, M. D., Kwong, A. D., Purcell, L. A., Saikatendu, K. S., Schmitz, U., Tallarico, J. A., & Lee, A. A. (2023). Accelerating antiviral drug discovery: lessons from COVID-19. *Nature Reviews Drug Discovery*, 22(7), 585–603. <https://doi.org/10.1038/s41573-023-00692-8>
- Wahab, N. Z. A., Saidi, S. I. M., Rahman, N. I. A., & Ibrahim, N. (2024). Evaluation of cytotoxicity and antiviral activity of Kyllinga nemoralis leaves and stems methanolic extract. *Journal of Applied Biology & Biotechnology*. <https://doi.org/10.7324/jabb.2024.159522>
- World Health Organization (WHO). (2022, December 8). *Chikungunya*. <https://www.who.int/news-room/fact-sheets/detail/chikungunya>

- Zabaleta, M. E., Forbes-Hernández, T. Y., Simal-Gandara, J., Quiles, J. L., Cinciosi, D., Bullon, B., Giampieri, F., & Battino, M. (2020). Effect of polyphenols on HER2-positive breast cancer and related miRNAs: Epigenomic regulation. *Food Research International*, 137, 109623. <https://doi.org/10.1016/j.foodres.2020.109623>
- Zhang, Y., Wei, Y., Li, J., & Li, J. (2012). Development and optimization of a direct plaque assay for human and avian metapneumoviruses. *Journal of Virological Methods*, 185(1), 61–68. <https://doi.org/10.1016/j.jviromet.2012.05.030>